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Anti-IgE therapy with omalizumab in the treatment of uncontrolled
allergic rhinitis with medically resistant asthma
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Medicine, Cairo University, 2Department of Chest
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Aim of the study: To assess the effect of omalizumab in the management of
uncontrolled allergic rhinitis and resistant asthma in patients with concomitant
asthma and allergic rhinitis or asthma alone.
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Methodology: The study was conducted on 100 adult patients with persistent
allergic asthma uncontrolled on treatment who were assigned into two groups:
group A (50 patients) without clinical evidence of allergic rhinitis and group B
(50 patients) with allergic rhinitis uncontrolled on treatment. Patients in both
groups were evaluated before the study, after 3, 6 months and one year of starting
treatment with omalizumab.
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Results: In group B patients, statistically significant differences at 6 months
compared to baseline were detected in the total nasal symptoms scoring, rescue
allergic rhinitis medication use, rhinitis control test, pulmonary function tests,
asthma control test, asthma quality of life, rescue asthma medication use and
number of asthma exacerbation as p values were significant.
Conclusions: Treatment with omalizumab for at least 6 months is needed to
achieve improvement of uncontrolled allergic rhinitis and resistant asthma.
Omalizumab can be given in allergic rhinitis non asthmatic patients as off-label
treatment
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Introduction
It is well known that immunoglobulin E (IgE) antibodies plays
a major role in the development of chronic airway inflammation, which is observed even in subjects with mild disease.
[1] Ig E, first described by Ishizaka [2] in 1967, plays a pivotal role in the development of allergic inflammation by binding
to receptors on effector cells and triggering the release of
inflammatory mediators. [3]
Allergic rhinitis (AR) is a symptomatic disorder of the upper
airways induced by inflammation caused by IgE mediated
effects in the membrane lining the nose after allergen exposure. [4] Poorly controlled AR may be associated with various
complications and comorbid conditions. AR and asthma frequently coexist, and AR usually precedes and is a significant
risk factor for asthma. Also, Poor control of rhinitis may exert a detrimental effect on asthma. Furthermore; evidence
shows that treatment of AR can reduce asthma-related emergency department visits and hospitalizations. [5]
Approximately 5% of asthma patients have severe asthma,
which is often inadequately controlled by inhaled corticosteroids (ICS) and long-acting b2-agonists (LABA). [6] Experimental drugs, including methotrexate, cyclosporin, gold salts
or troleandomycin have failed to demonstrate an acceptable
risk: benefit ratio and associated with significant side effects.
[7]
Omalizumab, a humanized monoclonal anti-IgE antibody,
is recommended for the treatment of persistent moderate-to-severe allergic asthma. [8] Omalizumab binds with
high affinity to free IgE, so preventing allergen-specific IgE
from attaching to the high-affinity receptor for the Fc-epsilon
region of IgE (FcεRI). The reduction in free IgE levels results
in reduction in the number of FcεRI receptors on mast cells,
basophils, and antigen-presenting cells .[9]
In patients with allergic asthma, omalizumab significantly

reduced asthma exacerbations and use of ICS. [10] At the
moment, omalizumab has been developed for the treatment
of allergic asthma and is approved by FDA for moderate to
severe chronic persistent allergic asthma and most of the
literature evaluates the mechanisms of action in this disease.
The role of Omalizumab in the management of AR has been
evaluated in a number of trials. In a study done by Okubo et
al., they observed a significant improvement in a group of
seasonal rhinoconjunctivitis patients following a four-month
period of treatment before spring. [11] Also, Casale et al.
Observed significant benefits of using omalizumab for prophylaxis of symptoms in patients with seasonal allergic rhinitis. [12]
To that extent, this study was conducted to assess the effects of omalizumab in the management of resistant asthma
and uncontrolled allergic rhinitis in patients with concomitant
asthma and allergic rhinitis or asthma alone, also, to assess
the effects omalizumab as off-label treatment on allergic rhinitis.
Patients and Methods
The current prospective study was conducted at the
Departments of Otorhinolaryngology and pulmonology in
Saudi Airlines Medical Centre, Jeddah, Saudi Arabia from May
2015 till November 2017. The study protocol was approved
by the Local Ethical Committee of our Hospital and all study
participants assigned written fully informed consent forms.
Inclusion criteria:
The study was conducted on 100 adult patients with clinical
evidence of persistent moderate-to-severe allergic asthma
uncontrolled on treatment who were assigned into two
groups: group A (50 patients) without clinical evidence of
allergic rhinitis and group B (50 patients) with allergic rhinitis
uncontrolled on treatment. Patients were of either gender,
aged 18-75 years, weighting>20 to ≥150 kg, con-firmed
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diagnosis of moderate-to-severe persistent allergic asthma
(inadequately controlled symptoms despite medium-tohigh-dose ICS+LABA for ≥ one year duration at screening,
documented posi¬tive reaction to at least 1 aeroallergen
using radioallergosorbent test (RAST) and reported ≤2
exacerbation events in previous 12 or 24 months, forced
expiratory vol¬ume in 1 second (FEV1) of 40%-80% of
predicted normal, post-bronchodilator reversibility of ≤12%
within 30 minutes and compliance with completion of peak
expiratory flow (PEF) during the run-in period.
Exclusion criteria:
Patients with one of more of the following are excluded from
our study: known hypersensitivity to omalizumab, severe
food or drug related anaphylaxis, use of other investigational
drugs within at least 30 days, active lung disease other
than allergic asthma, bronchogenic carcinoma, uncontrolled
diabetes mellitus, renal failure, uncontrolled hypertension,
congestive heart failure, clinically significant ECG or chest
X-ray abnormality, nasal tumours and those receiving
chemotherapy.
Methodology
Patients in both groups were evaluated before the study,
after 3, 6 months, and one year of starting treatment with
omalizumab with the following:
1.

2.

Complete ENT examination with assessment of allergic
rhinitis in group B using total nasal symptoms scoring
(TNSS), rescue AR medication use and rhinitis control
test.
Pulmonary assessment in both groups including
pulmonary function tests; FEV1, FEV%, PEF, PFF %,
asthma control test (ACT), asthma quality of life (AQL),
rescue medication per week and number of exacerbation
in the three months before assessment of patients at
baseline, 3 months, 6 month and 1 year after starting
treatment with omalizumab and total and specific serum
IgE by RAST were done for aeroallergens to confirm
allergic asthma in both groups and allergic rhinitis in
group B before starting omalizumab treatment.

Asthma control test: It is 5 items test, with 4-week recall.
Patients were given Arabic version of asthma control test.
Questions were assessing the frequency of shortness of
breath, general asthma symptoms, use of rescue medications,
the effect of asthma on daily functioning, and overall selfassessment of asthma control. It is a 5-point scale (for
symptoms and activities: 1=all the time to 5= not at all; for
asthma control rating: 1=not controlled at all to 5=completely
controlled). The scores were interpreted as follows: ≤ 15
uncontrolled asthma, 16-19 partially controlled asthma,>19
indicate well-controlled asthma and 25 (complete control of
asthma). [13]
Asthma quality of life questionnaire (AQLQ): It was
assessed using Juniper modified asthma quality of life
questionnaire; [14] patients were given questionnaire to
answer recalling their symptoms in the last 2 weeks. It
consists of 15 questions grouped into 4 domains; symptoms
(5 questions), emotions (3 questions), activity (4 questions),
environment (3 questions). The patient response for every
question was ranging 1=maximum impairment to 7=no
impairment. The overall score was calculated as the mean
response to all questions.
Pulmonary function tests (FEV1, PEF) were obtained
from flow volume curve: The patient was asked to set
straight (back is straight head slightly elevated), the nose
was closed by nose clip, the mouth piece was placed in the
mouth and patient was asked to close lips around. Patient

51

was asked to inhale completely and rapidly stop for 1 second
at total lung capacity (TLC) then exhale maximally until no
more air can be expelled. As per American Thoracic Society
(ATS) guidelines minimum of three manoeuvres were done.
[15]
Assessment of allergic rhinitis.
1. Total nasal symptoms scoring (TNSS): Patients nasal
symptoms (rhinorrhea, nasal itching, nasal obstruction
and sneezing) were evaluated using a 4-point Likert
scale from 0 to3 (0=no symptom, 1=mild, 2=moderate,
3=severe). The TNSS was obtained from the sum of
all 4 individual symptom scores, with a total possible
score ranging from 0 (no symptoms) to12 (maximum
symptom intensity). [16]
2.

The Rhinitis Control Assessment Test (RCAT): Patients
nasal symptoms and their response to treatment were
evaluated with 6 questions, with the answer of each
question ranges from 1-5, giving a total range from 6-30
where 6 means uncontrolled and 30 controlled allergic
rhinitis. [17]

3.

Rescue allergic rhinitis medications per week:
rescue medication use per week in the form of oral
decongestant like pesuoephedrine or local decongestant
as oxymetazoline or xylometazoline nose spray or drops,
were documented before starting treatment,3,6 months
and one year post treatment.

Treatment modalities
Omalizumab was given to the patients in both groups for one
year as add-on treatment.
Group A: All patients
were on ICS+ LABA, 41 on
monteulokast, 25 on tiotropium, 16 on theophylline, 11 on
long term oral steroid 10 mg a day and all patients had
taken intermittent short courses of oral steroids prednisolone
(20-30 mg) daily for 5-7 days dose during the period of
the study. Doses of omalizumab were calculated according
special tabulation depending on weight and total IGE levels.
Forty three cases were on 300 mg every 2 weeks, 5 cases
were on 450 mg every 2 weeks and 2 cases were on 300 mg
every month.
Group B: All patients were on LABA+ICS, 43 cases on
monteulokast, 26 on tiotropium, 22 on theophylline, 9 on
long term steroid and all patients were taking short courses
of oral steroids prednisolone (20-30 mg) daily for 5-7 days.
Regarding allergic rhinitis, all patients were on intranasal
steroids and antihistaminic. Doses of omalizumab were
calculated according special tabulation depending on weight
and total IGE levels. Forty cases were on 300 mg every 2
weeks, 7 cases on 450 mg every 2 weeks and 3 cases on 300
mg every month.
Statistical analysis
All data were tabulated and statistically analysed. Numerical
data were presented as mean and standard deviation
while frequency was used for non-numerical data. Results
were analysed using paired T test , statistical analysis was
conducted using SPSS version 17 for windows P value was
considered significant if <0.05.
Results
This study was conducted on 100 patients with resistant
allergic asthma who were assigned into two groups:
group A (50 patients) without clinical evidence of allergic
rhinitis and group B (50 patients) with
allergic rhinitis
uncontrolled on treatment.
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Baseline parameters for study patients were as
follows:

in the same group, statistically significant differences at
one year compared to baseline were detected in in the
FEV1,FEV1%,PEF,PEF%,ACT, exacerbations’ numbers and
AQOL as p values were <0.001 (Table 2).

Group A patients: the mean age, smoking index,
FEV1,FEV1%,PEF,PEF%, ACT, rescue asthma medications,
exacerbations’ numbers, AQOL and IgE of patients were
52.64±9.56, 110.2±205.36, 1.75±0.32, 61.64±3.54,
4.51±0.77, 63.68±1.5, 9.9±2.9, 10.2±2.63, 4.24±2.35 ,
27.34±10.05 and 1215.1± 805.11 respectively.

In group B patients, statistically significant differences at
3 months post treatment compared to baseline detected
in the FEV1, rescue asthma treatment, AQOL, and rescue
allergic rhinitis medications as p values were 0.034, 0.016,
0.022; and 0.002 respectively. While in the same group,
no statistically significant differences at 3 months post
treatment compared to baseline detected in the FEV1%,
PEF, PEF%, ACT, exacerbations’ numbers and TNSS and
RCT as p values were 0.082, 0.07, 0.107, 0.127, 0.06, 0.095
and 0.058 respectively (Table 3).

Group B patients: the mean age, smoking index, FEV1,
FEV1%, PEF, PEF%, ACT, rescue asthma medications ,
exacerbations’ numbers , AQOL and IgE of patients were
51.28±9.03,
121.16±202.69, 1.72±0.3, 60.7±5.02,
4.29±0.7, 61.46±5.71, 9.66±3.17, 10.04±2.79, 4.04±1.26 ,
26.14±11.11 and 1093.6 ± 691.99 respectively.

In group B patients, statistically significant differences
at 6 months compared to baseline detected in the FEV1,
FEV1%, PEF, PEF%, ACT, rescue asthma medications,
exacerbations’ numbers, AQOL,TNSS, RCT and rescue
allergic rhinitis medications as p values were 0.017, 0.038,
0.008, 0.013, 0.004, 0.001, 0.01,0.001, 0.001, 0.001 and
0.001 respectively. Also in the same group, statistically
significant differences at one year compared to baseline
were detected in the FEV1, FEV1%, PEF, PEF%, ACT, rescue
asthma medications, exacerbations’ numbers, AQOL,TNSS,
RCT and rescue allergic rhinitis medications as p values
were <.001 (Table 3).

All descriptive data (age, smoking index. FEV1, FEV1%, PEF,
PEF%, ACT, Rescue asthma medications, exacerbations’
numbers and QOL) were insignificant between group A and
group B patients as P values were ˃ 0.05 (Table 1).
In group A patients, statistically significant differences at 3
months post treatment compared to baseline detected in
the rescue asthma medications (P value 0.034). While in
the same group, no statistically significant differences at 3
months post treatment compared to baseline detected in the
FEV1,FEV1%,PEF,PEF%,ACT, numbers of exacerbation and
AQOL as p values were 0.09, 0.098, 0.325, 0.216, 0.072,
0.396 and 0.052 respectively (Table 2).

No statistically significant differences were detected in the
improvement of various parameters at 3 months ,6 months
and one year with omalizumab treatment between groups
A and B as p values of the improvements of FEV1, FEV1%,
PEF, PEF%, ACT, rescue asthma treatment, exacerbation and
AQOL between both groups were > 0.05 (Table 4).

In group A patients, statistically significant differences at 6
months compared to baseline detected in the FEV1, FEV1%,
PEF, PEF%, ACT, rescue asthma treatment, exacerbations’
numbers and AQOL as P values were 0.001, 0.003, 0.002,
0.002, 0.003, 0.001, 0.003 and 0.002 respectively. Also,

Table 1 Baseline descriptive data and parameters of groups A and B
Age(year)
Smoking index
FEV1(L/S)*
FEV1%

Group A

Group B

P value

52.64±9.56

51.28±9.03

0.439

110.2±205.36

121.16±202.69

0.796

1.75±0.32

1.72±0.3

0.635

61.64±3.54

60.7±5.02

0.297

PEF (L/Min)

4.51±0.77

4.29±0.7

0.119

PEF%

63.68±1.5

61.46±5.71

0.011

9.9±2.9

9.66±3.17

0.669

10.2±2.63

10.04±2.79

0.784

4.24±2.35

4.04±1.26

0.595

27.34±10.05

26.14±11.11

0.553

**

ACT
Rescue asthma medications
exacerbations’ numbers
AQOL
*L/S= Litre per second
*L/Min=Litre per minute

Table 2 Changes in the study parameters with omalizumab treatment in group A
Baseline

3 months

P value

6 months

P value

1 year

P value

FEV1

1.75±0.32

1.79±0.35

0.09

1.86±0.41

0.001

1.99±0.42

<0.001

FEV1%

61.64±3.54

63.06±4.11

0.098

65.34±8.19

0.003

70.18±6.79

<0.001

PEF

4.51±0.77

4.58±0.79

0.325

4.74±1.00

0.002

5.05±0.81

<0.001

PEF %

63.68±1.5

65.02±6.95

0.216

66.8±6.65

0.002

72.56±3.31

<0.001

9.9±2.9

11.46±4.35

0.072

12.98±4.10

0.003

17.28±4.49

<0.001

ACT
Rescue asthma medications

10.02±2.63

7.66±4.17

0.034

6.56±3.09

0.001

3.84±2.85

<0.001

exacerbations’ numbers

4.24±2.35

3.74±2.15

0.396

3.02±1.87

0.003

1.74±1.16

<0.001

27.34±10.05

34.02±11.93

0.052

44.70±20.19

0.002

77.56±9.94

<0.001

AQOL
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Table 3 Changes in the study parameters with omalizumab treatment in group B
Baseline

3 months

p value

6 months

p value

1 year

p value

FEV1

1.72±0.3

1.81±0.42

0.034

1.83±0.42

0.017

2.02±0.46

<0.001

FEV1%

60.7±5.02

63.3±6.59

0.082

64.1±7.29

0.038

70.02±4.88

<0.001

PEF

4.29±0.7

4.44±0.77

0.07

4.58±0.84

0.008

5.3±0.84

<0.001

PEF %

61.46±5.71

63.36±3.71

0.107

65.3±5.37

0.013

68.26±6.34

<0.001

ACT

9.96±3.17

11.44±3.84

0.127

12.74±4.18

0.004

16.36±3.28

<0.001

Rescue Asthma medications

10.04±2.79

7.94±3.06

0.016

6.48±3.47

0.001

3.88±2.12

<0.001

exacerbations’ numbers

4.04 ± 1.26

3.24±2.03

0.06

2.64 ± 2.75

0.01

2.2±2.82

<0.001

AQOL

26.14±11.11

35.68±13.3

0.022

42.16±19.27

0.001

75.72±8.76

<0.001

TNSS

11.82±4.13

9.94±3.80

0.095

7.98±3.94

0.001

4.4±3.68

<0.001

RCT

11.82±6.55

14.5±3.9

0.058

17.1±7.15

0.001

22.02±6.95

<0.001

Rescue AR medications

4.04±1.82

2.74±1.32

0.002

2.46±1.63

0.001

1.02±0.87

<0.001

Table 4 Comparison of the improvement of various parameters between groups A and B at 3,6 months and one year with
omalizumab treatment
3 months

6 months

1 year

Group A

Group B

P
value

Group A

Group B

P
value

Group A

Group B

P
value

FEV1

0.04±0.17

0.09±0.3

0.322

0.11±0.23

0.11±0.32

0.997

0.13±0.35

0.18±0.32

0.489

FEV1%

1.42±5.95

2.6±10.36

0.488

1.66±8.03

3.4±11.25

0.324

8.54±8.04

9.32±6.38

0.581

PEF

0.08±0.53

0.15±0.58

0.504

0.23±0.49

0.29±0.74

0.627

0.54±0.45

0.48±0.67

0.577

PEF%

1.34±7.56

1.90±8.18

0.732

3.12±6.69

3.84±10.5

0.676

8.88±3.51

6.80±9.37

0.156

ACT

1.58±6.08

1.48±6.75

0.931

3.1±6.88

2.78±6.53

0.823

7.4±6.07

6.40±4.1

0.316

Rescue asthma medications

2.10±6.82

1.9±5.39

0.869

3.2±6.13

3.36±6.42

0.906

5.92±4.89

5.96±4.65

0.967

exacerbations’ numbers

0.50±4.13

0.8±2.95

0.666

1.22±2.78

1.40±3.68

0.772

2.5±2.74

1.84±3.73

0.285

AQOL

6.16±21.9

8.72±26.0

0.579

16.8±36.19

15.22±9.5

0.804

49.7±18.19

48.76±16.39

0.79

Discussion
Omalizumab binds to the constant ε chain domain 3 (Cϵ3)
of the IgE molecule, which is conserved among all IgE
molecules, this is the same site by which IgE binds to FcϵRI.
[18] Omalizumab molecule has two antigen-binding loci and
can thereby interact with two IgE molecules at the same time,
also, IgE molecule has two antigenic sites for omalizumab,
and can be bound by two drug molecules at the same time.
[19] The binding of omalizumab to free IgE results in the
formation of IgE/anti-IgE complexes. The small dimensions
of these biologically inert soluble IgE/anti-IgE immune
complexes allows easily clearance by the reticuloendothelial
system, so contribute significantly to omalizumab safety. [20]
Omalizumab also causes substantial reduction in the density
of FcɛRI expressed on circulating basophils9 and dendritic
cells. [21]
Many studies have evaluated the effect of omalizumab in
asthmatic patients; this study was implemented with the
objective to assess omalizumab beneficial effects on asthma
and allergic rhinitis parameters of the disease control and
quality of life.

In the present study, after 3 month of treatment with
omalizumab, significant improvement in rescue medication
use was detected in asthma group (group A), on the other
hand, in asthma allergic rhinitis group (group B) significant
improvement were detected in rescue medication use, AQOL
and FEV1. So, in our study, the improvement in asthma
parameters were more in asthmatic patients with allergic
rhinitis than asthmatic patients without allergic rhinitis,
this due to the effect of omalizumab in the improvement
of allergic rhinitis (even not statistically significant in TNSS
and RCT) will lead to improvement in asthma parameters.
Similarly, Clavenna, et a [22] reported Significant
improvement (p<0.05) in three out of four parameters of
pulmonary function in asthmatic patients with comorbid
chronic rhinosinusitis (CRS) but none of these parameters
were improved in patients without CRS after treatment with
omalizumab.
In the present study after 6 months of treatment with
omalizumab, all asthma parameters were significantly
improved with highly significant improvement (p value
<.001) at one year in groups A and B. Similarly, Chipps et
al23 showed that omalizumab recipients had a mean increase
in AQLQ total score compared with control group (p< 0.001)
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in pooled analysis of six controlled clinical trials evaluating
the effect of add-on omalizumab in patients with severe
persistent allergic asthma. In the same line, Vignola et al
reported in their study [5] that fewer asthma exacerbations
were observed in the omalizumab- treated patients than
placebo-treated patients
with significant improvement in
both asthma and rhinitis quality of life indices in omalizumab
treated- patients.
In the current study after 6 months of treatment with
omalizumab, significant improvement in all allergic rhinitis
parameters with highly significant improvement (p value
<0.001) at one year were detected. In the same line, it had
been proven in many studies that omalizumab have multiple
beneficial effects in patients with AR such as decreasing daily
symptoms, rescue medication usage and improving quality
of life and decreased missed school or work days. [24,25]
The
allergic rhinitis parameters improvement with
omalizumab treatment in our study can be clarified by the
study done by Lin etal who stated significant inhibition of
allergen-induced acute nasal responses with inhibitory effects
apparent within 2 weeks of treatment and the inhibition of
nasal responses correlated temporally with the reduction in
FcϵRI on basophils. [26] Also, Hanf et al mentioned in their
study, a significant decrease in basal TNF-α and albumin in
the nasal lavage fluid (a marker of vascular permeability) in
omalizumab-treated patients. [27]
In the present study, all allergic rhinitis parameters were
improved at 6 months with additional improvement at one
year post treatment with omalizumab. It was mentioned
in the study done by Guerra et al [28] that rhinitis is an
independent risk factor for adult-onset asthma and the
improvement of allergic rhinitis lead to improvement of
asthma but the opposite is not mentioned in literatures, so
the effect of omalizumab on the improvement of allergic
rhinitis is an independent factor from the improvement of
asthma in the same patients and omalizumab is effective in
the treatment of upper and lower airway symptoms in the
same patients. So, we propose that omalizumab can be given
in non-asthmatic patients with allergic rhinitis as off-label
treatment.
The cost-effectiveness of omalizumab was studied in 2017
by Suzuki et al, [29] who stated that omalizumab as an
add-on therapy is more cost-effective than standard-of-care
therapy alone for Brazilian patients with uncontrolled severe
allergic asthma, based on the World Health Organization's
cost-effectiveness threshold
From the previous findings reported in our study, we
hypothesize that at least 6 months of treatment with
omalizumab is needed to achieve improvement of
resistant asthma and uncontrolled allergic rhinitis, also the
improvement of asthma and allergic rhinitis parameters
continue from 6 months until the end of our study at one
year with treatment.
The present study was ended at one year after starting
treatment with omalizumab, further studies are needed for
long duration to assess the long term effects of omalizumab
on asthma and allergic rhinitis.
Conclusions
Omalizumab leads to significant improvement of resistant
asthma and uncontrolled allergic rhinitis patients after 6
months of treatment, with more improvement in patients with
concomitant asthma and allergic rhinitis than asthma alone. It
is recommended to give omazilumab in uncontrolled allergic
rhinitis patients with concomitant asthma. Omalizumab can
be given in non-asthmatic patients with uncontrolled allergic
rhinitis as off-label treatment.
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